Bristol Myers (BMY) Gets a Buy Rating from BMO Capital

BMO Capital analyst Alex Arfaei maintained a Buy rating on Bristol Myers (BMY) today and set a price target of $60. The company’s shares opened today at $51.06.

According to, Arfaei is a 5-star analyst with an average return of 8.5% and a 70.2% success rate. Arfaei covers the Healthcare sector, focusing on stocks such as Elanco Animal Health Inc, Merck & Company, and Eli Lilly & Co.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Bristol Myers with a $56.50 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $70.05 and a one-year low of $44.30. Currently, Bristol Myers has an average volume of 14.27M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Bristol-Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It includes chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts